Simtra BioPharma Solutions’ Post

News on the collaboration between #Cytiva and #Rentschler: Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/dskqmumK #CDMO #viralvectors #genomicmedicine #genetherapy

Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/gPAk9D4z #CDMO #viralvectors #genomicmedicine #genetherapy

🎉 🚀 𝘼 𝙈𝙤𝙣𝙪𝙢𝙚𝙣𝙩𝙖𝙡 𝙇𝙚𝙖𝙥 𝙛𝙤𝙧 𝙑𝙞𝙫𝙪𝙨𝙤𝙛𝙩 𝙏𝙚𝙘𝙝𝙣𝙤𝙡𝙤𝙜𝙞𝙚𝙨! 🎉 🎊 I am overjoyed to share with you a landmark moment for our company. Our solid partnership with a leading pharmaceutical company in India(with 20000+ employees worldwide) has been fortified with a 3-year extension of our innovative L&D tech solution. This journey of collaboration over the past 2 years has been nothing short of inspiring. Their renewed commitment for an additional 3 years is a resounding vote of confidence in the value and effectiveness of our solutions. This extension is not just a contract; it’s a statement of trust, a reflection of the results we’ve achieved together, and a promise of the potential we have yet to unlock. More importantly, it reflects the deep trust and confidence our clients have in our offerings. As we look to the future, we’re excited for the endless possibilities that lie ahead. Together, we will continue to innovate, excel, and lead the way in transforming the pharmaceutical industry. #Vivusoft #PharmaInnovation #LearningSolutions #DigitalTransformation #ClientTrust #SuccessStory #TeamVivusoft #ThankYouTeam #OnwardAndUpward #SalesWin #CustomerSuccess #Partnership #Success #Growth #LearningAndDevelopment #TechSolutions #Pharmaceuticals

Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/dfcXTz2X #CDMO #viralvectors #genomicmedicine #genetherapy

Nonceba Sibanda, GMP Scientist USP at Rentschler Biopharma, said it best, "You're helping people who help people. We make a brilliant team". And we cannot agree more! See how a collaboration with Cytiva is bringing Rentschler Biopharma both efficiency and flexibility to their operations. The ultimate goal? Improving more patients’ lives. Watch the full story here: https://lnkd.in/gNCuQv4b #CDMO #viralvectors #genomicmedicine #genetherapy

Shield Therapeutics plc (AIM:STX, OTCQX:SHIEF)'s third-quarter trading update for Accrufer in the US market shows its tie-up with Viatris and expanded sales team are “bearing fruit,” according to analysts.   Accrufer is a non-salt based oral therapy used to treat iron deficiency in adults.   Analysts at Cavendish said key performance indicators such as total scrips, new scrips, retention rate, and net realised price are all showing significant improvement compared to the first half of 2023.   The number of US representatives promoting Accrufer increased from 16 to 30 in the first quarter of 2023, and by May 2023, a total of 100 had been trained to sell the product.   Third quarter unaudited sales were US$4.1 million, above the broker’s forecasts of US$3.6 million, and the company said trading is in-line with expectations.   More at #Proactive #ProactiveInvestors #AIM #OTCQX #STX #SHIEF http://ow.ly/uuY71055xNy

ICYMI...Calyx CTMS Select delivers the reliability and global operational support of a proven #CTMS with more features for lower cost, enabling faster implementation times for small/mid-sized #Biopharma and #CROs. Learn more. https://lnkd.in/gDVDpEdx #ChooseCalyx #CTMS #ClinicalTrialManagement

CDMOs play a crucial in helping pharmaceutical and biotech companies, develop and manufacture drugs offering comprehensive end-to-end services. Some of the major reasons why CDMO services are needed include; cost efficiency,production at scale and great expertise. Interesting to see how this market is expected to grow by 2030 at a whopping amount of over 230 billion . Mentioned below are some of the big names in the game with Lonza, Thermo Fischer and Catalent topping the chart. With Africa being the new Wild West and the African Union’s ambitious target to fulfill 60 percent of the continent’s vaccine needs by 2040, the goal and dream is to see the development of these CDMOs in the continent. Better days ahead

CDMOs eye industrywide growth in 2025 as many spurn BIOSECURE Act, CPHI research shows - Fierce Pharma After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound in 2025. That's according to new research from CPHI Milan ahead of the group's manufacturing conference next month. As it stands, 49% of the CDMO industry is “highly positive” on contract services growth in the next 18 months, CPHI said in a release, citing new research pooling insights from 280 pharma companies. The optimistic mood comes despite an uneven recovery in the biopharma industry after the pandemic. While funding has flowed to later-stage projects, early-stage assets continue to face a funding deficit, Gil Roth, president of the Pharma & Biopharma Outsourcing Association said in a statement. “This means that the lifeblood of CDMOs—projects moving through the development pipeline and smaller customers sticking with key service providers—remains hobbled,” Roth said. https://lnkd.in/eegVNZKf